Premium
The use of r‐HuEpo in the treatment of anaemia related to myelodysplasia (MDS)
Author(s) -
Rose Esther H.,
Abels Robert I.,
Nelson Richard A.,
McCullough Doreen M.,
Lessin Lawrence,
Johnson R. W.
Publication year - 1995
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.1995.tb08421.x
Subject(s) - medicine , erythropoietin , myelodysplastic syndromes , anemia , blood transfusion , surgery , gastroenterology , pediatrics , bone marrow
One hundred and sixteen (116) anaemic patients with myelodysplastic syndromes (MDS) were treated with recombinant human erythropoietin (r‐HuEpo) in an openlabel, multicentre, compassionate treatment trial; 100 patients received therapy for ≧ 4 weeks and were evaluable for efficacy. The distribution of FAB subtypes was: 44 RA, 40 RARS, eight RAEB, two RAEB‐t, one CMML, and five not specified. Mean baseline haematocrit was 24.5%, and the mean prestudy transfusion requirement in the 12 weeks immediately prior to study entry was 6.5 units. r‐HuEpo treatment was initiated at a dose of 150U/kg three times weekly, with dose escalations of 50U/kg monthly (up to 300U/kg 3 x /week) permitted if the haematocrit failed to rise. Response to therapy was defined as either an increase in haematocrit of ≧ 6 percentage points over baseline, unrelated to transfusion, or a ≧ 50% decrease in transfusion requirement in the last 3 months of study treatment, compared to the baseline period (12 weeks), By these criteria, 28% (28/100) of patients responded to r‐HuEpo treatment. Overall, 86% (24/28) of patients responding to therapy had baseline Epo levels ≧ 100 mU/ml. Response rates by FAB subtype were: RA 39% (17/44), RARS 17.5% (7/40) and RAEB 12.5% (1/8). Additionally, a 54% (15/28) response rate was seen in RA patients with baseline EPo levels ≧ 100 mU/ml. Responses to therapy were durable and generally occurred at r‐HuEpo doses of 150‐200 U/kg t.i.w. There were no reports of thrombosis, seizures or therapy‐related hypertension. The data show that patients with MDS, especially those with the RA and RARS subtypes, can benefit from treatment with r‐HuEpo. Those patients with baseline Epo levels ≧ 100 mU/ml were most likely to respond to therapy.